Actualités

TSN-driven technologies are key for advanced data governance in the industry

Confirming the safety, efficacy and quality of medications is paramount in the pharmaceutical sector, which requires robust data governance strategies. In the world of Pharma 4.0, these need to accommodate an ever-increasing volume of data for responsive process control, quality assurance and quality auditing via reliable and secure network platforms. Technologies that incorporate gigabit Ethernet and Time-Sensitive Networking (TSN) are exactly what is needed.

John Browett, General Manager at CLPA Europe, looks at how TSN-driven gigabit Ethernet can help pharmaceutical manufacturers improve their operations and regulatory compliance activities.

By creating smart and responsive facilities, pharmaceutical manufacturers can optimise yield of regulatory compliant, high-quality medications. The latest advances in sensor technology can offer ever greater process transparency on the factory floor via the data produced. This can provide clear benefits that increase process and quality control/assurance as well as regulatory compliance.

While generating data is the first step in creating greater process transparency, it is crucial to gather these pieces of information in order to analyse them and turn them into process knowledge. This, in turn, can offer actionable insight to improve production processes as well as provide the foundation of quality audits and reports.

Look at the bandwidth

To unlock these opportunities a network technology that can handle the constantly growing flow of data from sensors and analytical equipment needs to be implemented. In practice, this means offering sufficient bandwidth to transfer as many data packets as possible within a given timeframe without any packet loss or network congestion.

Although many existing Ethernet systems offer a maximum bandwidth of 100 Mbit/s, pharmaceutical manufacturers that aim to build truly smart, connected factories should leverage more advanced solutions. The highest bandwidth currently available for industrial Ethernet networks is in the gigabit range. By adopting a technology with this capacity, companies can futureproof their industrial communications and lay the foundations for next-level data traffic.

Determinism and convergence

In addition to offering sufficient bandwidth, the ideal network should also be able to provide a deterministic method of data transmission, to assure predictable information flows. The latest Ethernet technology, Time-Sensitive Networking (TSN), brings this capability to the table, thanks to its defining IEEE 802.1 standards that assure tight synchronisation across the network along with providing methods to ensure predictable transmission of all data types. As a result, time-critical data from drives and controllers on the factory floor, e.g. from tableting lines, can be transmitted on the same network used for other Ethernet devices with less time critical requirements, such as vision systems or bar code readers.

The end result is converged networks, where it is possible to merge operational technology (OT) and information technology (IT) systems for truly responsive, smart data-driven manufacturing. More precisely, TSN’s determinism ensures the predictable delivery of all process data flows that OT requires while offering a framework to support IT functions for higher-level enterprise systems. As a result, companies can benefit from real-time decision-making opportunities, accurate operational control as well as unmatched databases for quality compliance reporting.

Furthermore, convergence can reduce the number of industrial networks required while supporting the creation of simpler architectures, as different types of traffic can be transferred on the same system.

The right solution is right here

Pharmaceutical manufacturers wanting to benefit from smart, connected plants and enterprises can implement them today. CC-Link IE TSN, the first open Gigabit Ethernet with TSN capabilities satisfies both the need for high bandwidth and convergence.

By implementing CC-Link IE TSN, pharmaceutical producers can achieve a number of key business benefits. In particular, simpler network architectures and machine designs, greater process transparency and better management, as well as optimised productivity and better integration of OT and IT systems.

Editorial contact:
DMA Europa Ltd: Anne-Marie Howe
Tel: +44 (0)1562 751436 Fax: +44 (0)1562 748315
Web: www.dmaeuropa.com
Email: anne-marie@dmaeuropa.com

Company contact:
CLPA-Europe: John Browett
Tel: +44 (0) 7768 338708 Fax: +49 (0) 2102 532 9740
Web: eu.cc-link.org
Email: john.browett@eu.cc-link.org